nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylprednisolone—ABCB1—esophageal cancer	0.725	1	CbGaD
Methylprednisolone—Ca++ increased—Capecitabine—esophageal cancer	0.00842	0.0396	CcSEcCtD
Methylprednisolone—Aseptic necrosis—Methotrexate—esophageal cancer	0.00682	0.032	CcSEcCtD
Methylprednisolone—Paraplegia—Methotrexate—esophageal cancer	0.00581	0.0273	CcSEcCtD
Methylprednisolone—Oesophageal candidiasis—Capecitabine—esophageal cancer	0.00578	0.0272	CcSEcCtD
Methylprednisolone—Personality change—Capecitabine—esophageal cancer	0.00551	0.0259	CcSEcCtD
Methylprednisolone—Diplegia—Methotrexate—esophageal cancer	0.00542	0.0254	CcSEcCtD
Methylprednisolone—Glucose tolerance impaired—Cisplatin—esophageal cancer	0.00532	0.025	CcSEcCtD
Methylprednisolone—Monoplegia—Methotrexate—esophageal cancer	0.00508	0.0239	CcSEcCtD
Methylprednisolone—Papilloedema—Cisplatin—esophageal cancer	0.00451	0.0212	CcSEcCtD
Methylprednisolone—Arachnoiditis—Methotrexate—esophageal cancer	0.00431	0.0202	CcSEcCtD
Methylprednisolone—Infarction—Capecitabine—esophageal cancer	0.00381	0.0179	CcSEcCtD
Methylprednisolone—Telangiectasia—Methotrexate—esophageal cancer	0.00334	0.0157	CcSEcCtD
Methylprednisolone—Blood potassium decreased—Capecitabine—esophageal cancer	0.00278	0.013	CcSEcCtD
Methylprednisolone—Blindness—Cisplatin—esophageal cancer	0.00259	0.0122	CcSEcCtD
Methylprednisolone—Depressed mood—Capecitabine—esophageal cancer	0.00236	0.0111	CcSEcCtD
Methylprednisolone—Diabetic—Methotrexate—esophageal cancer	0.00236	0.0111	CcSEcCtD
Methylprednisolone—Optic neuritis—Cisplatin—esophageal cancer	0.00233	0.0109	CcSEcCtD
Methylprednisolone—Osteonecrosis—Methotrexate—esophageal cancer	0.00211	0.00991	CcSEcCtD
Methylprednisolone—ABCB1—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00209	0.0394	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—KRT17—esophageal cancer	0.002	0.0378	CbGpPWpGaD
Methylprednisolone—Opportunistic infection—Methotrexate—esophageal cancer	0.00195	0.00917	CcSEcCtD
Methylprednisolone—Leukoderma—Methotrexate—esophageal cancer	0.00185	0.00869	CcSEcCtD
Methylprednisolone—Necrosis—Cisplatin—esophageal cancer	0.00183	0.00857	CcSEcCtD
Methylprednisolone—Impaired healing—Methotrexate—esophageal cancer	0.00182	0.00854	CcSEcCtD
Methylprednisolone—Cognitive disorder—Methotrexate—esophageal cancer	0.00182	0.00854	CcSEcCtD
Methylprednisolone—Hirsutism—Capecitabine—esophageal cancer	0.00182	0.00853	CcSEcCtD
Methylprednisolone—Abscess—Cisplatin—esophageal cancer	0.00181	0.0085	CcSEcCtD
Methylprednisolone—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.00178	0.00834	CcSEcCtD
Methylprednisolone—Infection—Carboplatin—esophageal cancer	0.00173	0.00813	CcSEcCtD
Methylprednisolone—Embolism—Capecitabine—esophageal cancer	0.00165	0.00773	CcSEcCtD
Methylprednisolone—Hypercalcaemia—Capecitabine—esophageal cancer	0.00152	0.00714	CcSEcCtD
Methylprednisolone—Hepatomegaly—Capecitabine—esophageal cancer	0.00149	0.00701	CcSEcCtD
Methylprednisolone—Hiccups—Cisplatin—esophageal cancer	0.00143	0.00673	CcSEcCtD
Methylprednisolone—Osteoporosis—Methotrexate—esophageal cancer	0.0014	0.00659	CcSEcCtD
Methylprednisolone—Skin exfoliation—Cisplatin—esophageal cancer	0.00137	0.00642	CcSEcCtD
Methylprednisolone—Fungal infection—Capecitabine—esophageal cancer	0.00137	0.00642	CcSEcCtD
Methylprednisolone—Fluid retention—Cisplatin—esophageal cancer	0.00136	0.00639	CcSEcCtD
Methylprednisolone—Multiple fractures—Methotrexate—esophageal cancer	0.00135	0.00635	CcSEcCtD
Methylprednisolone—Fracture—Methotrexate—esophageal cancer	0.00135	0.00635	CcSEcCtD
Methylprednisolone—Neuropathy—Cisplatin—esophageal cancer	0.00135	0.00632	CcSEcCtD
Methylprednisolone—Exemestane—CYP19A1—esophageal cancer	0.00133	0.144	CrCbGaD
Methylprednisolone—Hydrocortisone—ANXA1—esophageal cancer	0.00133	0.144	CrCbGaD
Methylprednisolone—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.00132	0.00621	CcSEcCtD
Methylprednisolone—Tingling sensation—Capecitabine—esophageal cancer	0.00131	0.00617	CcSEcCtD
Methylprednisolone—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00129	0.0243	CbGpPWpGaD
Methylprednisolone—Petechiae—Capecitabine—esophageal cancer	0.00128	0.00603	CcSEcCtD
Methylprednisolone—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00128	0.0242	CbGpPWpGaD
Methylprednisolone—Testolactone—CYP19A1—esophageal cancer	0.00127	0.138	CrCbGaD
Methylprednisolone—NR3C1—Nuclear Receptors—NR1I2—esophageal cancer	0.00125	0.0236	CbGpPWpGaD
Methylprednisolone—Folliculitis—Methotrexate—esophageal cancer	0.00125	0.00587	CcSEcCtD
Methylprednisolone—Embolism—Methotrexate—esophageal cancer	0.00123	0.00575	CcSEcCtD
Methylprednisolone—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00115	0.00539	CcSEcCtD
Methylprednisolone—ABCB1—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00114	0.0215	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CRTC1—esophageal cancer	0.00111	0.0209	CbGpPWpGaD
Methylprednisolone—Amnesia—Cisplatin—esophageal cancer	0.00111	0.0052	CcSEcCtD
Methylprednisolone—Inflammation—Capecitabine—esophageal cancer	0.00109	0.00511	CcSEcCtD
Methylprednisolone—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00107	0.00505	CcSEcCtD
Methylprednisolone—Hiccups—Capecitabine—esophageal cancer	0.00106	0.00496	CcSEcCtD
Methylprednisolone—Fungal infection—Methotrexate—esophageal cancer	0.00102	0.00478	CcSEcCtD
Methylprednisolone—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00102	0.0192	CbGpPWpGaD
Methylprednisolone—Skin exfoliation—Capecitabine—esophageal cancer	0.00101	0.00474	CcSEcCtD
Methylprednisolone—Fluid retention—Capecitabine—esophageal cancer	0.001	0.00471	CcSEcCtD
Methylprednisolone—Necrosis—Methotrexate—esophageal cancer	0.001	0.0047	CcSEcCtD
Methylprednisolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALDOB—esophageal cancer	0.000994	0.0187	CbGpPWpGaD
Methylprednisolone—Abscess—Methotrexate—esophageal cancer	0.000994	0.00467	CcSEcCtD
Methylprednisolone—Irritability—Cisplatin—esophageal cancer	0.000993	0.00466	CcSEcCtD
Methylprednisolone—Neuropathy—Capecitabine—esophageal cancer	0.000992	0.00466	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—NR1I2—esophageal cancer	0.000991	0.0187	CbGpPWpGaD
Methylprednisolone—Dexamethasone—ANXA1—esophageal cancer	0.000988	0.107	CrCbGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—KRT14—esophageal cancer	0.000978	0.0184	CbGpPWpGaD
Methylprednisolone—Oesophagitis—Capecitabine—esophageal cancer	0.000965	0.00453	CcSEcCtD
Methylprednisolone—Petechiae—Methotrexate—esophageal cancer	0.000956	0.00449	CcSEcCtD
Methylprednisolone—Ecchymosis—Capecitabine—esophageal cancer	0.000955	0.00448	CcSEcCtD
Methylprednisolone—Breast disorder—Cisplatin—esophageal cancer	0.00094	0.00441	CcSEcCtD
Methylprednisolone—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.000895	0.0169	CbGpPWpGaD
Methylprednisolone—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.000892	0.0168	CbGpPWpGaD
Methylprednisolone—Thrombophlebitis—Capecitabine—esophageal cancer	0.000886	0.00416	CcSEcCtD
Methylprednisolone—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.000882	0.00414	CcSEcCtD
Methylprednisolone—Diabetes mellitus—Capecitabine—esophageal cancer	0.000882	0.00414	CcSEcCtD
Methylprednisolone—Pancreatitis—Cisplatin—esophageal cancer	0.000882	0.00414	CcSEcCtD
Methylprednisolone—Sweating increased—Cisplatin—esophageal cancer	0.000876	0.00411	CcSEcCtD
Methylprednisolone—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.000823	0.0155	CbGpPWpGaD
Methylprednisolone—Amnesia—Capecitabine—esophageal cancer	0.000816	0.00383	CcSEcCtD
Methylprednisolone—Increased appetite—Capecitabine—esophageal cancer	0.000816	0.00383	CcSEcCtD
Methylprednisolone—Inflammation—Methotrexate—esophageal cancer	0.000811	0.00381	CcSEcCtD
Methylprednisolone—Vasculitis—Methotrexate—esophageal cancer	0.000806	0.00378	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX1—esophageal cancer	0.000805	0.0152	CbGpPWpGaD
Methylprednisolone—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00079	0.00371	CcSEcCtD
Methylprednisolone—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00079	0.0149	CbGpPWpGaD
Methylprednisolone—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000786	0.00369	CcSEcCtD
Methylprednisolone—Myocardial infarction—Cisplatin—esophageal cancer	0.000786	0.00369	CcSEcCtD
Methylprednisolone—Cardiac failure—Capecitabine—esophageal cancer	0.000786	0.00369	CcSEcCtD
Methylprednisolone—Osteoarthritis—Capecitabine—esophageal cancer	0.000767	0.0036	CcSEcCtD
Methylprednisolone—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.000755	0.0142	CbGpPWpGaD
Methylprednisolone—Skin exfoliation—Methotrexate—esophageal cancer	0.000751	0.00353	CcSEcCtD
Methylprednisolone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000737	0.0139	CbGpPWpGaD
Methylprednisolone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000737	0.0139	CbGpPWpGaD
Methylprednisolone—Bradycardia—Cisplatin—esophageal cancer	0.000733	0.00344	CcSEcCtD
Methylprednisolone—Irritability—Capecitabine—esophageal cancer	0.000732	0.00344	CcSEcCtD
Methylprednisolone—Cardiac arrest—Capecitabine—esophageal cancer	0.000729	0.00342	CcSEcCtD
Methylprednisolone—Mood swings—Capecitabine—esophageal cancer	0.000726	0.00341	CcSEcCtD
Methylprednisolone—Ecchymosis—Methotrexate—esophageal cancer	0.000711	0.00334	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Cisplatin—esophageal cancer	0.000707	0.00332	CcSEcCtD
Methylprednisolone—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.000704	0.0133	CbGpPWpGaD
Methylprednisolone—Pulmonary oedema—Methotrexate—esophageal cancer	0.0007	0.00329	CcSEcCtD
Methylprednisolone—Visual impairment—Cisplatin—esophageal cancer	0.000694	0.00326	CcSEcCtD
Methylprednisolone—Breast disorder—Capecitabine—esophageal cancer	0.000693	0.00325	CcSEcCtD
Methylprednisolone—ABCB1—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000689	0.013	CbGpPWpGaD
Methylprednisolone—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.000683	0.0129	CbGpPWpGaD
Methylprednisolone—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000676	0.00318	CcSEcCtD
Methylprednisolone—Muscular weakness—Capecitabine—esophageal cancer	0.000676	0.00318	CcSEcCtD
Methylprednisolone—Eye disorder—Cisplatin—esophageal cancer	0.000673	0.00316	CcSEcCtD
Methylprednisolone—Cardiac disorder—Cisplatin—esophageal cancer	0.000668	0.00314	CcSEcCtD
Methylprednisolone—Abdominal distension—Capecitabine—esophageal cancer	0.000667	0.00313	CcSEcCtD
Methylprednisolone—Thrombophlebitis—Methotrexate—esophageal cancer	0.000659	0.0031	CcSEcCtD
Methylprednisolone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000657	0.0124	CbGpPWpGaD
Methylprednisolone—Diabetes mellitus—Methotrexate—esophageal cancer	0.000656	0.00308	CcSEcCtD
Methylprednisolone—NR3C1—Endoderm Differentiation—SOX2—esophageal cancer	0.000653	0.0123	CbGpPWpGaD
Methylprednisolone—Bronchospasm—Capecitabine—esophageal cancer	0.000652	0.00306	CcSEcCtD
Methylprednisolone—Immune system disorder—Cisplatin—esophageal cancer	0.00065	0.00305	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Cisplatin—esophageal cancer	0.000649	0.00305	CcSEcCtD
Methylprednisolone—Sweating increased—Capecitabine—esophageal cancer	0.000646	0.00303	CcSEcCtD
Methylprednisolone—Arrhythmia—Cisplatin—esophageal cancer	0.000643	0.00302	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX3—esophageal cancer	0.000637	0.012	CbGpPWpGaD
Methylprednisolone—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.000629	0.0118	CbGpPWpGaD
Methylprednisolone—ABCB1—ABC-family proteins mediated transport—ABCC2—esophageal cancer	0.000627	0.0118	CbGpPWpGaD
Methylprednisolone—Erythema—Cisplatin—esophageal cancer	0.000627	0.00294	CcSEcCtD
Methylprednisolone—Malnutrition—Cisplatin—esophageal cancer	0.000627	0.00294	CcSEcCtD
Methylprednisolone—Weight increased—Capecitabine—esophageal cancer	0.000603	0.00283	CcSEcCtD
Methylprednisolone—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.000591	0.0111	CbGpPWpGaD
Methylprednisolone—Infestation—Capecitabine—esophageal cancer	0.000591	0.00277	CcSEcCtD
Methylprednisolone—Infestation NOS—Capecitabine—esophageal cancer	0.000591	0.00277	CcSEcCtD
Methylprednisolone—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00059	0.00277	CcSEcCtD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.000585	0.011	CbGpPWpGaD
Methylprednisolone—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000583	0.00274	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Cisplatin—esophageal cancer	0.000581	0.00273	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000579	0.00272	CcSEcCtD
Methylprednisolone—Myocardial infarction—Capecitabine—esophageal cancer	0.000579	0.00272	CcSEcCtD
Methylprednisolone—Osteoarthritis—Methotrexate—esophageal cancer	0.000571	0.00268	CcSEcCtD
Methylprednisolone—Malaise—Cisplatin—esophageal cancer	0.000565	0.00265	CcSEcCtD
Methylprednisolone—ABCB1—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000551	0.0104	CbGpPWpGaD
Methylprednisolone—Irritability—Methotrexate—esophageal cancer	0.000545	0.00256	CcSEcCtD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—SFN—esophageal cancer	0.000544	0.0103	CbGpPWpGaD
Methylprednisolone—Convulsion—Cisplatin—esophageal cancer	0.000543	0.00255	CcSEcCtD
Methylprednisolone—Mood swings—Methotrexate—esophageal cancer	0.000541	0.00254	CcSEcCtD
Methylprednisolone—Bradycardia—Capecitabine—esophageal cancer	0.00054	0.00254	CcSEcCtD
Methylprednisolone—Myalgia—Cisplatin—esophageal cancer	0.000533	0.0025	CcSEcCtD
Methylprednisolone—Haemoglobin—Capecitabine—esophageal cancer	0.000533	0.0025	CcSEcCtD
Methylprednisolone—Prednisolone—CYP2A6—esophageal cancer	0.000532	0.0578	CrCbGaD
Methylprednisolone—Rhinitis—Capecitabine—esophageal cancer	0.000532	0.0025	CcSEcCtD
Methylprednisolone—Anxiety—Cisplatin—esophageal cancer	0.000532	0.0025	CcSEcCtD
Methylprednisolone—Haemorrhage—Capecitabine—esophageal cancer	0.000531	0.00249	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00053	0.00249	CcSEcCtD
Methylprednisolone—Discomfort—Cisplatin—esophageal cancer	0.000527	0.00247	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Capecitabine—esophageal cancer	0.000521	0.00245	CcSEcCtD
Methylprednisolone—Breast disorder—Methotrexate—esophageal cancer	0.000516	0.00242	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Cisplatin—esophageal cancer	0.000511	0.0024	CcSEcCtD
Methylprednisolone—Visual impairment—Capecitabine—esophageal cancer	0.000511	0.0024	CcSEcCtD
Methylprednisolone—Infection—Cisplatin—esophageal cancer	0.000508	0.00238	CcSEcCtD
Methylprednisolone—Nervous system disorder—Cisplatin—esophageal cancer	0.000501	0.00235	CcSEcCtD
Methylprednisolone—Tachycardia—Cisplatin—esophageal cancer	0.000499	0.00234	CcSEcCtD
Methylprednisolone—Skin disorder—Cisplatin—esophageal cancer	0.000497	0.00233	CcSEcCtD
Methylprednisolone—Betamethasone—CYP19A1—esophageal cancer	0.000496	0.054	CrCbGaD
Methylprednisolone—Eye disorder—Capecitabine—esophageal cancer	0.000496	0.00233	CcSEcCtD
Methylprednisolone—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.000494	0.00932	CbGpPWpGaD
Methylprednisolone—Hyperhidrosis—Cisplatin—esophageal cancer	0.000494	0.00232	CcSEcCtD
Methylprednisolone—Cardiac disorder—Capecitabine—esophageal cancer	0.000492	0.00231	CcSEcCtD
Methylprednisolone—Pancreatitis—Methotrexate—esophageal cancer	0.000484	0.00227	CcSEcCtD
Methylprednisolone—Angiopathy—Capecitabine—esophageal cancer	0.000481	0.00226	CcSEcCtD
Methylprednisolone—Immune system disorder—Capecitabine—esophageal cancer	0.000479	0.00225	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Capecitabine—esophageal cancer	0.000478	0.00224	CcSEcCtD
Methylprednisolone—Hypotension—Cisplatin—esophageal cancer	0.000478	0.00224	CcSEcCtD
Methylprednisolone—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.000475	0.00896	CbGpPWpGaD
Methylprednisolone—Arrhythmia—Capecitabine—esophageal cancer	0.000474	0.00223	CcSEcCtD
Methylprednisolone—NR3C1—Adipogenesis—CYP26A1—esophageal cancer	0.000469	0.00884	CbGpPWpGaD
Methylprednisolone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000466	0.00219	CcSEcCtD
Methylprednisolone—Mental disorder—Capecitabine—esophageal cancer	0.000465	0.00218	CcSEcCtD
Methylprednisolone—Dexamethasone—NOS2—esophageal cancer	0.000463	0.0503	CrCbGaD
Methylprednisolone—Malnutrition—Capecitabine—esophageal cancer	0.000462	0.00217	CcSEcCtD
Methylprednisolone—Erythema—Capecitabine—esophageal cancer	0.000462	0.00217	CcSEcCtD
Methylprednisolone—Paraesthesia—Cisplatin—esophageal cancer	0.000459	0.00216	CcSEcCtD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000454	0.00855	CbGpPWpGaD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000454	0.00855	CbGpPWpGaD
Methylprednisolone—Infestation NOS—Methotrexate—esophageal cancer	0.00044	0.00207	CcSEcCtD
Methylprednisolone—Infestation—Methotrexate—esophageal cancer	0.00044	0.00207	CcSEcCtD
Methylprednisolone—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.000434	0.00817	CbGpPWpGaD
Methylprednisolone—Ill-defined disorder—Capecitabine—esophageal cancer	0.000428	0.00201	CcSEcCtD
Methylprednisolone—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000425	0.008	CbGpPWpGaD
Methylprednisolone—Sweating—Methotrexate—esophageal cancer	0.000422	0.00198	CcSEcCtD
Methylprednisolone—Feeling abnormal—Cisplatin—esophageal cancer	0.000421	0.00198	CcSEcCtD
Methylprednisolone—Malaise—Capecitabine—esophageal cancer	0.000416	0.00196	CcSEcCtD
Methylprednisolone—Vertigo—Capecitabine—esophageal cancer	0.000415	0.00195	CcSEcCtD
Methylprednisolone—Syncope—Capecitabine—esophageal cancer	0.000414	0.00194	CcSEcCtD
Methylprednisolone—Loss of consciousness—Capecitabine—esophageal cancer	0.000406	0.00191	CcSEcCtD
Methylprednisolone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—esophageal cancer	0.000405	0.00764	CbGpPWpGaD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000405	0.00762	CbGpPWpGaD
Methylprednisolone—Hypertension—Capecitabine—esophageal cancer	0.000399	0.00187	CcSEcCtD
Methylprednisolone—Haemoglobin—Methotrexate—esophageal cancer	0.000397	0.00186	CcSEcCtD
Methylprednisolone—Haemorrhage—Methotrexate—esophageal cancer	0.000395	0.00185	CcSEcCtD
Methylprednisolone—Dexamethasone—CYP1B1—esophageal cancer	0.000393	0.0428	CrCbGaD
Methylprednisolone—Myalgia—Capecitabine—esophageal cancer	0.000393	0.00185	CcSEcCtD
Methylprednisolone—Arthralgia—Capecitabine—esophageal cancer	0.000393	0.00185	CcSEcCtD
Methylprednisolone—Anxiety—Capecitabine—esophageal cancer	0.000392	0.00184	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00039	0.00183	CcSEcCtD
Methylprednisolone—Discomfort—Capecitabine—esophageal cancer	0.000388	0.00182	CcSEcCtD
Methylprednisolone—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.000383	0.00722	CbGpPWpGaD
Methylprednisolone—Visual impairment—Methotrexate—esophageal cancer	0.000381	0.00179	CcSEcCtD
Methylprednisolone—Confusional state—Capecitabine—esophageal cancer	0.00038	0.00178	CcSEcCtD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.000377	0.0071	CbGpPWpGaD
Methylprednisolone—Hypersensitivity—Cisplatin—esophageal cancer	0.000377	0.00177	CcSEcCtD
Methylprednisolone—Infection—Capecitabine—esophageal cancer	0.000374	0.00176	CcSEcCtD
Methylprednisolone—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.000374	0.00704	CbGpPWpGaD
Methylprednisolone—NR3C1—Endoderm Differentiation—SMAD4—esophageal cancer	0.000372	0.00702	CbGpPWpGaD
Methylprednisolone—Shock—Capecitabine—esophageal cancer	0.000371	0.00174	CcSEcCtD
Methylprednisolone—Nervous system disorder—Capecitabine—esophageal cancer	0.00037	0.00174	CcSEcCtD
Methylprednisolone—Eye disorder—Methotrexate—esophageal cancer	0.000369	0.00173	CcSEcCtD
Methylprednisolone—Tachycardia—Capecitabine—esophageal cancer	0.000368	0.00173	CcSEcCtD
Methylprednisolone—Asthenia—Cisplatin—esophageal cancer	0.000367	0.00172	CcSEcCtD
Methylprednisolone—Cardiac disorder—Methotrexate—esophageal cancer	0.000367	0.00172	CcSEcCtD
Methylprednisolone—Skin disorder—Capecitabine—esophageal cancer	0.000366	0.00172	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Capecitabine—esophageal cancer	0.000364	0.00171	CcSEcCtD
Methylprednisolone—NR3C1—Circadian Clock—HIF1A—esophageal cancer	0.000361	0.00681	CbGpPWpGaD
Methylprednisolone—Angiopathy—Methotrexate—esophageal cancer	0.000358	0.00168	CcSEcCtD
Methylprednisolone—Immune system disorder—Methotrexate—esophageal cancer	0.000357	0.00167	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Methotrexate—esophageal cancer	0.000356	0.00167	CcSEcCtD
Methylprednisolone—Hypotension—Capecitabine—esophageal cancer	0.000352	0.00165	CcSEcCtD
Methylprednisolone—Diarrhoea—Cisplatin—esophageal cancer	0.00035	0.00164	CcSEcCtD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.000348	0.00655	CbGpPWpGaD
Methylprednisolone—Mental disorder—Methotrexate—esophageal cancer	0.000346	0.00162	CcSEcCtD
Methylprednisolone—Malnutrition—Methotrexate—esophageal cancer	0.000344	0.00161	CcSEcCtD
Methylprednisolone—Erythema—Methotrexate—esophageal cancer	0.000344	0.00161	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000343	0.00161	CcSEcCtD
Methylprednisolone—Insomnia—Capecitabine—esophageal cancer	0.000341	0.0016	CcSEcCtD
Methylprednisolone—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000339	0.0064	CbGpPWpGaD
Methylprednisolone—Paraesthesia—Capecitabine—esophageal cancer	0.000338	0.00159	CcSEcCtD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.000336	0.00633	CbGpPWpGaD
Methylprednisolone—Dyspepsia—Capecitabine—esophageal cancer	0.000332	0.00156	CcSEcCtD
Methylprednisolone—Vomiting—Cisplatin—esophageal cancer	0.000325	0.00153	CcSEcCtD
Methylprednisolone—Fatigue—Capecitabine—esophageal cancer	0.000325	0.00153	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD4—esophageal cancer	0.000324	0.0061	CbGpPWpGaD
Methylprednisolone—Rash—Cisplatin—esophageal cancer	0.000322	0.00151	CcSEcCtD
Methylprednisolone—Dermatitis—Cisplatin—esophageal cancer	0.000322	0.00151	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Methotrexate—esophageal cancer	0.000319	0.0015	CcSEcCtD
Methylprednisolone—Feeling abnormal—Capecitabine—esophageal cancer	0.000311	0.00146	CcSEcCtD
Methylprednisolone—Malaise—Methotrexate—esophageal cancer	0.00031	0.00146	CcSEcCtD
Methylprednisolone—Vertigo—Methotrexate—esophageal cancer	0.000309	0.00145	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000308	0.00145	CcSEcCtD
Methylprednisolone—Dexamethasone—ABCC2—esophageal cancer	0.000307	0.0334	CrCbGaD
Methylprednisolone—NR3C1—Regulation of Androgen receptor activity—CREBBP—esophageal cancer	0.000304	0.00573	CbGpPWpGaD
Methylprednisolone—Nausea—Cisplatin—esophageal cancer	0.000304	0.00143	CcSEcCtD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—BAX—esophageal cancer	0.000303	0.00572	CbGpPWpGaD
Methylprednisolone—Dexamethasone—CYP2A6—esophageal cancer	0.000303	0.033	CrCbGaD
Methylprednisolone—Urticaria—Capecitabine—esophageal cancer	0.000299	0.00141	CcSEcCtD
Methylprednisolone—Abdominal pain—Capecitabine—esophageal cancer	0.000298	0.0014	CcSEcCtD
Methylprednisolone—Convulsion—Methotrexate—esophageal cancer	0.000298	0.0014	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—HIF1A—esophageal cancer	0.000298	0.00561	CbGpPWpGaD
Methylprednisolone—NR3C1—Circadian Clock—CREBBP—esophageal cancer	0.000295	0.00556	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—ENO1—esophageal cancer	0.000293	0.00552	CbGpPWpGaD
Methylprednisolone—Myalgia—Methotrexate—esophageal cancer	0.000293	0.00137	CcSEcCtD
Methylprednisolone—Arthralgia—Methotrexate—esophageal cancer	0.000293	0.00137	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000291	0.00136	CcSEcCtD
Methylprednisolone—Discomfort—Methotrexate—esophageal cancer	0.000289	0.00136	CcSEcCtD
Methylprednisolone—Dexamethasone—CYP19A1—esophageal cancer	0.000289	0.0314	CrCbGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000288	0.00543	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000287	0.0054	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000284	0.00536	CbGpPWpGaD
Methylprednisolone—Confusional state—Methotrexate—esophageal cancer	0.000283	0.00133	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Methotrexate—esophageal cancer	0.000281	0.00132	CcSEcCtD
Methylprednisolone—Infection—Methotrexate—esophageal cancer	0.000279	0.00131	CcSEcCtD
Methylprednisolone—Triamcinolone—PTGS2—esophageal cancer	0.000279	0.0303	CrCbGaD
Methylprednisolone—Hypersensitivity—Capecitabine—esophageal cancer	0.000278	0.0013	CcSEcCtD
Methylprednisolone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—esophageal cancer	0.000276	0.0052	CbGpPWpGaD
Methylprednisolone—Nervous system disorder—Methotrexate—esophageal cancer	0.000275	0.00129	CcSEcCtD
Methylprednisolone—NR3C1—Endoderm Differentiation—NOTCH1—esophageal cancer	0.000275	0.00517	CbGpPWpGaD
Methylprednisolone—Skin disorder—Methotrexate—esophageal cancer	0.000273	0.00128	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Methotrexate—esophageal cancer	0.000271	0.00127	CcSEcCtD
Methylprednisolone—Asthenia—Capecitabine—esophageal cancer	0.00027	0.00127	CcSEcCtD
Methylprednisolone—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.00027	0.00509	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—esophageal cancer	0.000269	0.00506	CbGpPWpGaD
Methylprednisolone—Pruritus—Capecitabine—esophageal cancer	0.000267	0.00125	CcSEcCtD
Methylprednisolone—Hypotension—Methotrexate—esophageal cancer	0.000262	0.00123	CcSEcCtD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—SST—esophageal cancer	0.000261	0.00492	CbGpPWpGaD
Methylprednisolone—Diarrhoea—Capecitabine—esophageal cancer	0.000258	0.00121	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000256	0.0012	CcSEcCtD
Methylprednisolone—Insomnia—Methotrexate—esophageal cancer	0.000254	0.00119	CcSEcCtD
Methylprednisolone—Paraesthesia—Methotrexate—esophageal cancer	0.000252	0.00118	CcSEcCtD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000251	0.00474	CbGpPWpGaD
Methylprednisolone—Dizziness—Capecitabine—esophageal cancer	0.000249	0.00117	CcSEcCtD
Methylprednisolone—Dyspepsia—Methotrexate—esophageal cancer	0.000247	0.00116	CcSEcCtD
Methylprednisolone—Fatigue—Methotrexate—esophageal cancer	0.000242	0.00114	CcSEcCtD
Methylprednisolone—Vomiting—Capecitabine—esophageal cancer	0.00024	0.00113	CcSEcCtD
Methylprednisolone—Rash—Capecitabine—esophageal cancer	0.000238	0.00112	CcSEcCtD
Methylprednisolone—Dermatitis—Capecitabine—esophageal cancer	0.000237	0.00111	CcSEcCtD
Methylprednisolone—Headache—Capecitabine—esophageal cancer	0.000236	0.00111	CcSEcCtD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000234	0.0044	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000232	0.00438	CbGpPWpGaD
Methylprednisolone—Feeling abnormal—Methotrexate—esophageal cancer	0.000231	0.00109	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000229	0.00108	CcSEcCtD
Methylprednisolone—Betamethasone—PTGS2—esophageal cancer	0.000228	0.0248	CrCbGaD
Methylprednisolone—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000225	0.00425	CbGpPWpGaD
Methylprednisolone—Nausea—Capecitabine—esophageal cancer	0.000224	0.00105	CcSEcCtD
Methylprednisolone—Urticaria—Methotrexate—esophageal cancer	0.000223	0.00105	CcSEcCtD
Methylprednisolone—Abdominal pain—Methotrexate—esophageal cancer	0.000222	0.00104	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—esophageal cancer	0.000216	0.00408	CbGpPWpGaD
Methylprednisolone—Prednisone—ABCB1—esophageal cancer	0.000215	0.0234	CrCbGaD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000215	0.00405	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—esophageal cancer	0.000214	0.00404	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	0.000214	0.00402	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CDKN2A—esophageal cancer	0.000213	0.00401	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of Androgen receptor activity—EP300—esophageal cancer	0.000207	0.0039	CbGpPWpGaD
Methylprednisolone—Hypersensitivity—Methotrexate—esophageal cancer	0.000207	0.000971	CcSEcCtD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000205	0.00387	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	0.000205	0.00386	CbGpPWpGaD
Methylprednisolone—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000205	0.00386	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000203	0.00382	CbGpPWpGaD
Methylprednisolone—Asthenia—Methotrexate—esophageal cancer	0.000201	0.000945	CcSEcCtD
Methylprednisolone—NR3C1—Circadian Clock—EP300—esophageal cancer	0.000201	0.00379	CbGpPWpGaD
Methylprednisolone—Pruritus—Methotrexate—esophageal cancer	0.000199	0.000932	CcSEcCtD
Methylprednisolone—Prednisolone—ABCB1—esophageal cancer	0.000198	0.0215	CrCbGaD
Methylprednisolone—Betamethasone—ABCB1—esophageal cancer	0.000194	0.0211	CrCbGaD
Methylprednisolone—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000192	0.00363	CbGpPWpGaD
Methylprednisolone—Diarrhoea—Methotrexate—esophageal cancer	0.000192	0.000901	CcSEcCtD
Methylprednisolone—Dizziness—Methotrexate—esophageal cancer	0.000186	0.000871	CcSEcCtD
Methylprednisolone—NR3C1—Adipogenesis—HIF1A—esophageal cancer	0.000181	0.00342	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.00018	0.0034	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CCND1—esophageal cancer	0.00018	0.00339	CbGpPWpGaD
Methylprednisolone—Vomiting—Methotrexate—esophageal cancer	0.000178	0.000838	CcSEcCtD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000177	0.00334	CbGpPWpGaD
Methylprednisolone—Rash—Methotrexate—esophageal cancer	0.000177	0.000831	CcSEcCtD
Methylprednisolone—Dermatitis—Methotrexate—esophageal cancer	0.000177	0.00083	CcSEcCtD
Methylprednisolone—Headache—Methotrexate—esophageal cancer	0.000176	0.000825	CcSEcCtD
Methylprednisolone—NR3C1—Generic Transcription Pathway—NR1I2—esophageal cancer	0.000171	0.00323	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	0.000168	0.00316	CbGpPWpGaD
Methylprednisolone—Nausea—Methotrexate—esophageal cancer	0.000167	0.000782	CcSEcCtD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000166	0.00314	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—EP300—esophageal cancer	0.000166	0.00312	CbGpPWpGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000165	0.00312	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000163	0.00308	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000158	0.00297	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000157	0.00296	CbGpPWpGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000156	0.00293	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—esophageal cancer	0.000155	0.00292	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000154	0.00289	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—esophageal cancer	0.000153	0.00289	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	0.000153	0.00288	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000152	0.00287	CbGpPWpGaD
Methylprednisolone—Hydrocortisone—ABCB1—esophageal cancer	0.000152	0.0165	CrCbGaD
Methylprednisolone—NR3C1—Adipogenesis—RB1—esophageal cancer	0.000148	0.00278	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—esophageal cancer	0.000147	0.00278	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—EP300—esophageal cancer	0.000146	0.00275	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—MYC—esophageal cancer	0.000144	0.00272	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	0.000137	0.00258	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000134	0.00253	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000133	0.00252	CbGpPWpGaD
Methylprednisolone—Dexamethasone—PTGS2—esophageal cancer	0.000133	0.0144	CrCbGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—esophageal cancer	0.000128	0.00242	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000128	0.00241	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000126	0.00238	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000124	0.00234	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000123	0.00231	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000122	0.00231	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—CASP8—esophageal cancer	0.000119	0.00225	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—TP53—esophageal cancer	0.000119	0.00223	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000115	0.00217	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000114	0.00214	CbGpPWpGaD
Methylprednisolone—Dexamethasone—ABCB1—esophageal cancer	0.000113	0.0123	CrCbGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000112	0.00211	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—SMG6—esophageal cancer	0.000109	0.00205	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.000108	0.00203	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000107	0.00201	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—CDKN1A—esophageal cancer	0.000106	0.002	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000106	0.002	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—esophageal cancer	0.000104	0.00197	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	0.000103	0.00194	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	9.97e-05	0.00188	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—NOTCH2—esophageal cancer	9.64e-05	0.00182	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	9.46e-05	0.00178	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	9.4e-05	0.00177	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	9.33e-05	0.00176	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	9.04e-05	0.0017	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	9.02e-05	0.0017	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	8.94e-05	0.00169	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	8.84e-05	0.00167	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	8.76e-05	0.00165	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—EP300—esophageal cancer	8.73e-05	0.00164	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	8.65e-05	0.00163	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	8.65e-05	0.00163	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	8.38e-05	0.00158	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	8.29e-05	0.00156	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—NR1I2—esophageal cancer	8.24e-05	0.00155	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—SMAD4—esophageal cancer	8.1e-05	0.00153	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	7.13e-05	0.00134	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—HIST1H2BM—esophageal cancer	7.07e-05	0.00133	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	7.03e-05	0.00132	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	6.7e-05	0.00126	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	6.61e-05	0.00125	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	6.55e-05	0.00124	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—NOTCH1—esophageal cancer	5.97e-05	0.00113	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	5.95e-05	0.00112	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	5.88e-05	0.00111	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	5.85e-05	0.0011	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—SLC52A3—esophageal cancer	5.84e-05	0.0011	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—BLVRB—esophageal cancer	5.84e-05	0.0011	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—PSME1—esophageal cancer	5.49e-05	0.00103	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—PSME2—esophageal cancer	5.49e-05	0.00103	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—CREBBP—esophageal cancer	5.41e-05	0.00102	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—NOTCH3—esophageal cancer	5.18e-05	0.000976	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	5.05e-05	0.000951	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—SLC10A2—esophageal cancer	4.97e-05	0.000936	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CA1—esophageal cancer	4.97e-05	0.000936	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	4.9e-05	0.000924	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	4.79e-05	0.000903	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—NOTCH2—esophageal cancer	4.64e-05	0.000875	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CA2—esophageal cancer	4.54e-05	0.000856	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.33e-05	0.000816	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PLCE1—esophageal cancer	4.22e-05	0.000796	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ADH7—esophageal cancer	4.22e-05	0.000796	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.19e-05	0.00079	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3.99e-05	0.000751	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—SMAD4—esophageal cancer	3.9e-05	0.000735	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ADH1B—esophageal cancer	3.7e-05	0.000698	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.62e-05	0.000683	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—BLVRB—esophageal cancer	3.6e-05	0.000679	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—SLC52A3—esophageal cancer	3.6e-05	0.000679	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—TYMP—esophageal cancer	3.54e-05	0.000667	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.47e-05	0.000655	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CYP26A1—esophageal cancer	3.44e-05	0.000649	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.4e-05	0.00064	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ALOX15—esophageal cancer	3.36e-05	0.000633	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—MYC—esophageal cancer	3.21e-05	0.000605	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTO1—esophageal cancer	3.2e-05	0.000603	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—TPI1—esophageal cancer	3.2e-05	0.000603	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ALDOB—esophageal cancer	3.07e-05	0.000579	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CA1—esophageal cancer	3.06e-05	0.000577	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—SLC10A2—esophageal cancer	3.06e-05	0.000577	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GAPDH—esophageal cancer	2.95e-05	0.000557	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.95e-05	0.000556	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CRABP1—esophageal cancer	2.93e-05	0.000552	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—NOTCH1—esophageal cancer	2.87e-05	0.000542	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.85e-05	0.000538	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CA2—esophageal cancer	2.8e-05	0.000528	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GNG7—esophageal cancer	2.79e-05	0.000525	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ALDH2—esophageal cancer	2.61e-05	0.000492	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—CREBBP—esophageal cancer	2.61e-05	0.000491	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ADH7—esophageal cancer	2.6e-05	0.000491	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PLCE1—esophageal cancer	2.6e-05	0.000491	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTT1—esophageal cancer	2.48e-05	0.000468	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.45e-05	0.000463	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ENO1—esophageal cancer	2.33e-05	0.000438	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTGS1—esophageal cancer	2.33e-05	0.000438	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.32e-05	0.000438	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PSME1—esophageal cancer	2.29e-05	0.000432	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PSME2—esophageal cancer	2.29e-05	0.000432	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.28e-05	0.00043	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—TYMP—esophageal cancer	2.18e-05	0.000411	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.12e-05	0.0004	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.07e-05	0.00039	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.98e-05	0.000373	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—TPI1—esophageal cancer	1.97e-05	0.000372	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.97e-05	0.000372	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.89e-05	0.000356	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.86e-05	0.000351	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.82e-05	0.000343	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.8e-05	0.00034	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GNG7—esophageal cancer	1.72e-05	0.000323	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—HMOX1—esophageal cancer	1.7e-05	0.00032	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.61e-05	0.000303	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—MYC—esophageal cancer	1.55e-05	0.000292	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.53e-05	0.000288	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.51e-05	0.000285	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.43e-05	0.00027	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ENO1—esophageal cancer	1.43e-05	0.00027	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PSME1—esophageal cancer	1.41e-05	0.000266	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PSME2—esophageal cancer	1.41e-05	0.000266	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.22e-05	0.00023	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.15e-05	0.000216	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CREBBP—esophageal cancer	1.09e-05	0.000205	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.05e-05	0.000197	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ABCB1—esophageal cancer	1e-05	0.000189	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—NOS3—esophageal cancer	9.75e-06	0.000184	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTGS2—esophageal cancer	8.91e-06	0.000168	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—EP300—esophageal cancer	7.41e-06	0.00014	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CREBBP—esophageal cancer	6.71e-06	0.000126	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—NOS3—esophageal cancer	6.01e-06	0.000113	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTGS2—esophageal cancer	5.49e-06	0.000104	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PIK3CA—esophageal cancer	5.48e-06	0.000103	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—EP300—esophageal cancer	4.57e-06	8.61e-05	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.38e-06	6.37e-05	CbGpPWpGaD
